Log In
BCIQ
Print this Print this
 

SGN-352A

  Manage Alerts
Collapse Summary General Information
Company Seattle Genetics Inc.
DescriptionAntibody-drug conjugate (ADC) targeting CD352
Molecular Target
Mechanism of ActionAntibody-drug conjugate
Therapeutic ModalityBiologic: Antibody-drug conjugate
Latest Stage of DevelopmentPreclinical
Standard IndicationMultiple myeloma (MM)
Indication DetailsTreat multiple myeloma (MM)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today